612 related articles for article (PubMed ID: 17117182)
1. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up.
Villa LL; Costa RL; Petta CA; Andrade RP; Paavonen J; Iversen OE; Olsson SE; Høye J; Steinwall M; Riis-Johannessen G; Andersson-Ellstrom A; Elfgren K; Krogh Gv; Lehtinen M; Malm C; Tamms GM; Giacoletti K; Lupinacci L; Railkar R; Taddeo FJ; Bryan J; Esser MT; Sings HL; Saah AJ; Barr E
Br J Cancer; 2006 Dec; 95(11):1459-66. PubMed ID: 17117182
[TBL] [Abstract][Full Text] [Related]
2. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women.
Muñoz N; Kjaer SK; Sigurdsson K; Iversen OE; Hernandez-Avila M; Wheeler CM; Perez G; Brown DR; Koutsky LA; Tay EH; Garcia PJ; Ault KA; Garland SM; Leodolter S; Olsson SE; Tang GW; Ferris DG; Paavonen J; Steben M; Bosch FX; Dillner J; Huh WK; Joura EA; Kurman RJ; Majewski S; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan JT; Lupinacci LC; Giacoletti KE; Sings HL; James MK; Hesley TM; Barr E; Haupt RM
J Natl Cancer Inst; 2010 Mar; 102(5):325-39. PubMed ID: 20139221
[TBL] [Abstract][Full Text] [Related]
3. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial.
; Dillner J; Kjaer SK; Wheeler CM; Sigurdsson K; Iversen OE; Hernandez-Avila M; Perez G; Brown DR; Koutsky LA; Tay EH; García P; Ault KA; Garland SM; Leodolter S; Olsson SE; Tang GW; Ferris DG; Paavonen J; Lehtinen M; Steben M; Bosch FX; Joura EA; Majewski S; Muñoz N; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan JT; Maansson R; Lu S; Vuocolo S; Hesley TM; Barr E; Haupt R
BMJ; 2010 Jul; 341():c3493. PubMed ID: 20647284
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of quadrivalent human papillomavirus (types 6, 11, 16 and 18) vaccine (GARDASIL) in Japanese women aged 18-26 years.
Yoshikawa H; Ebihara K; Tanaka Y; Noda K
Cancer Sci; 2013 Apr; 104(4):465-72. PubMed ID: 23331518
[TBL] [Abstract][Full Text] [Related]
5. Spotlight on quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine(Gardasil®) in the prevention of premalignant genital lesions, genital cancer, and genital warts in women.
McCormack PL; Joura EA
BioDrugs; 2011 Oct; 25(5):339-43. PubMed ID: 21942919
[TBL] [Abstract][Full Text] [Related]
6. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial.
Villa LL; Costa RL; Petta CA; Andrade RP; Ault KA; Giuliano AR; Wheeler CM; Koutsky LA; Malm C; Lehtinen M; Skjeldestad FE; Olsson SE; Steinwall M; Brown DR; Kurman RJ; Ronnett BM; Stoler MH; Ferenczy A; Harper DM; Tamms GM; Yu J; Lupinacci L; Railkar R; Taddeo FJ; Jansen KU; Esser MT; Sings HL; Saah AJ; Barr E
Lancet Oncol; 2005 May; 6(5):271-8. PubMed ID: 15863374
[TBL] [Abstract][Full Text] [Related]
7. Quadrivalent human papillomavirus vaccine.
Barr E; Tamms G
Clin Infect Dis; 2007 Sep; 45(5):609-7. PubMed ID: 17682997
[TBL] [Abstract][Full Text] [Related]
8. Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial.
Reisinger KS; Block SL; Lazcano-Ponce E; Samakoses R; Esser MT; Erick J; Puchalski D; Giacoletti KE; Sings HL; Lukac S; Alvarez FB; Barr E
Pediatr Infect Dis J; 2007 Mar; 26(3):201-9. PubMed ID: 17484215
[TBL] [Abstract][Full Text] [Related]
9. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
Markowitz LE; Dunne EF; Saraiya M; Lawson HW; Chesson H; Unger ER; ;
MMWR Recomm Rep; 2007 Mar; 56(RR-2):1-24. PubMed ID: 17380109
[TBL] [Abstract][Full Text] [Related]
10. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial.
Muñoz N; Manalastas R; Pitisuttithum P; Tresukosol D; Monsonego J; Ault K; Clavel C; Luna J; Myers E; Hood S; Bautista O; Bryan J; Taddeo FJ; Esser MT; Vuocolo S; Haupt RM; Barr E; Saah A
Lancet; 2009 Jun; 373(9679):1949-57. PubMed ID: 19493565
[TBL] [Abstract][Full Text] [Related]
11. Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (gardasil(®)): a review of its use in the prevention of premalignant anogenital lesions, cervical and anal cancers, and genital warts.
McCormack PL
Drugs; 2014 Jul; 74(11):1253-83. PubMed ID: 25022951
[TBL] [Abstract][Full Text] [Related]
12. Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data.
Joura EA; Garland SM; Paavonen J; Ferris DG; Perez G; Ault KA; Huh WK; Sings HL; James MK; Haupt RM;
BMJ; 2012 Mar; 344():e1401. PubMed ID: 22454089
[TBL] [Abstract][Full Text] [Related]
13. Efficacy, immunogenicity, and safety of a quadrivalent HPV vaccine in men: results of an open-label, long-term extension of a randomised, placebo-controlled, phase 3 trial.
Goldstone SE; Giuliano AR; Palefsky JM; Lazcano-Ponce E; Penny ME; Cabello RE; Moreira ED; Baraldi E; Jessen H; Ferenczy A; Kurman R; Ronnett BM; Stoler MH; Bautista O; Das R; Group T; Luxembourg A; Zhou HJ; Saah A
Lancet Infect Dis; 2022 Mar; 22(3):413-425. PubMed ID: 34780705
[TBL] [Abstract][Full Text] [Related]
14. A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions.
Kjaer SK; Sigurdsson K; Iversen OE; Hernandez-Avila M; Wheeler CM; Perez G; Brown DR; Koutsky LA; Tay EH; García P; Ault KA; Garland SM; Leodolter S; Olsson SE; Tang GW; Ferris DG; Paavonen J; Lehtinen M; Steben M; Bosch FX; Dillner J; Joura EA; Majewski S; Muñoz N; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan J; Maansson R; Lu S; Vuocolo S; Hesley TM; Saah A; Barr E; Haupt RM
Cancer Prev Res (Phila); 2009 Oct; 2(10):868-78. PubMed ID: 19789295
[TBL] [Abstract][Full Text] [Related]
15. Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection.
FUTURE II Study Group
J Infect Dis; 2007 Nov; 196(10):1438-46. PubMed ID: 18008221
[TBL] [Abstract][Full Text] [Related]
16. Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (Gardasil®): a review of its use in the prevention of premalignant genital lesions, genital cancer and genital warts in women.
McCormack PL; Joura EA
Drugs; 2010 Dec; 70(18):2449-74. PubMed ID: 21142263
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials.
Joura EA; Leodolter S; Hernandez-Avila M; Wheeler CM; Perez G; Koutsky LA; Garland SM; Harper DM; Tang GW; Ferris DG; Steben M; Jones RW; Bryan J; Taddeo FJ; Bautista OM; Esser MT; Sings HL; Nelson M; Boslego JW; Sattler C; Barr E; Paavonen J
Lancet; 2007 May; 369(9574):1693-702. PubMed ID: 17512854
[TBL] [Abstract][Full Text] [Related]
18. Cost-consequences evaluation between bivalent and quadrivalent HPV vaccines in Italy: the potential impact of different cross-protection profiles.
Capri S; Gasparini R; Panatto D; Demarteau N
Gynecol Oncol; 2011 Jun; 121(3):514-21. PubMed ID: 21334734
[TBL] [Abstract][Full Text] [Related]
19. Long-term follow-up observation of the safety, immunogenicity, and effectiveness of Gardasil™ in adult women.
Luna J; Plata M; Gonzalez M; Correa A; Maldonado I; Nossa C; Radley D; Vuocolo S; Haupt RM; Saah A
PLoS One; 2013; 8(12):e83431. PubMed ID: 24391768
[TBL] [Abstract][Full Text] [Related]
20. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women.
Joura EA; Giuliano AR; Iversen OE; Bouchard C; Mao C; Mehlsen J; Moreira ED; Ngan Y; Petersen LK; Lazcano-Ponce E; Pitisuttithum P; Restrepo JA; Stuart G; Woelber L; Yang YC; Cuzick J; Garland SM; Huh W; Kjaer SK; Bautista OM; Chan IS; Chen J; Gesser R; Moeller E; Ritter M; Vuocolo S; Luxembourg A;
N Engl J Med; 2015 Feb; 372(8):711-23. PubMed ID: 25693011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]